Skip to main content

Advertisement

Log in

Effect of TU-100, a traditional Japanese medicine, administered after hepatic resection in patients with liver cancer: a multi-center, phase III trial (JFMC40-1001)

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

This multi-center, phase III trial assesses the efficacy of daikenchuto (TU-100) on gastrointestinal disorders after hepatic resection (UMIN Registration No. 000003103).

Materials and methods

A total of 231 patients, who underwent hepatic resection at 26 Japanese centers, were enrolled. Patients were randomly assigned to receive either oral doses (15 g/day, three times a day) of TU-100 or placebo control from preoperative day 3 to postoperative day 10, except on the day of surgery. Primary end points were the time from extubation until the first postoperative bowel movement (FBM-T), serum C-reactive protein (CRP) and ammonia levels.

Results

Finally, 209 patients (TU-100: n = 108, placebo: n = 101) were included in the statistical analysis. The median FBM-T was 88.2 h (95 % CI 74.0–94.1) in the TU-100 group and 93.1 h (95 % CI 83.3–99.4) in the placebo group, demonstrating that TU-100 accelerated the time to first bowel movement significantly more than placebo control. Serum CRP levels did not differ significantly during the study period, although serum CRP levels in the TU-100 group tended to be lower than those in the placebo group in patients with grade B liver damage. Meanwhile, the two groups had similar serum ammonia levels. TU-100-related serious adverse events did not occur during the study.

Conclusions

TU-100 appears to improve gastrointestinal dysmotility and reduce serum CRP levels in patients with grade B liver damage after hepatectomy. TU-100 is an effective treatment option after hepatic resection in patients with liver cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

TU-100:

Daikenchuto

JFMC:

Japanese Foundation for Multidisciplinary Treatment of Cancer

FBM-T:

The time from extubation until the first postoperative bowel movement

CRP:

C-reactive protein

COX-2:

Cyclooxygenase-2

CGRP:

Calcitonin gene-related peptide

VIP:

Vasoactive intestinal polypeptide

AUC:

Area under curve

SD:

Standard deviation

CRLR:

Calcitonin receptor like receptor

Ramp1:

Receptor activity modifying protein 1

ADM:

Adrenomedullin

References

  1. Furukawa Y, Hanyu N, Nakada K et al (1999) Effects of the Chinese herb medicine “Dai-kenchu-to” on GI motility and for treatment of bowel obstruction. Gastroenterology 116:A811

    Google Scholar 

  2. Iwai N, Kume Y, Kimura O et al (2007) Effects of herbal medicine Dai-Kenchu-to on anorectal function in children with severe constipation. Eur J Pediatr Surg 17:115–118

    Article  CAS  PubMed  Google Scholar 

  3. Sakakibara R, Odaka T, Lui Z et al (2005) Dietary herb extract dai-kenchu-to ameliorates constipation in parkinsonian patients (Parkinson’s disease and multiple system atrophy). Mov Disord 20:261–262

    Article  PubMed  Google Scholar 

  4. Ohya T, Usui Y, Arii S et al (2003) Effect of dai-kenchu-to on obstructive bowel disease in children. Am J Chin Med 31:129–135

    Article  PubMed  Google Scholar 

  5. Nakamura T, Sakai A, Isogami I et al (2002) Abatement of morphine-induced slowing in gastrointestinal transit by Dai-kenchu-to, a traditional Japanese herbal medicine. Jpn J Pharmacol 88:217–221

    Article  CAS  PubMed  Google Scholar 

  6. Satoh K, Kase Y, Yuzurihara M et al (2003) Effect of Dai-kenchu-to (Da-Jian-Zhong-Tang) on the delayed intestinal propulsion induced by chlorpromazine in mice. J Ethnopharmacol 86:37–44

    Article  PubMed  Google Scholar 

  7. Satoh K, Hayakawa T, Kase Y et al (2001) Mechanisms for contractile effect of dai-kenchu-to in isolated guinea pig ileum. Dig Dis Sci 46:250–256

    Article  CAS  PubMed  Google Scholar 

  8. Hayakawa T, Kase Y, Saito K et al (1999) Effects of Dai-kenchu-to on intestinal obstruction following laparotomy. J Smooth Muscle Res 35:47–54

    Article  CAS  PubMed  Google Scholar 

  9. Yoshikawa K, Kurita N, Higashijima J et al (2008) Kampo medicine “Dai-kenchu-to” prevents bacterial translocation in rats. Dig Dis Sci 53:1824–1831

    Article  PubMed  Google Scholar 

  10. Chikakiyo M, Shimada M, Nakao T et al (2012) Kampo medicine “Dai-kenchu-to” prevents CPT-11-induced small-intestinal injury in rats. Surg Today 42:60–67

    Article  PubMed  Google Scholar 

  11. Sato Y, Katagiri F, Inoue S et al (2004) Dai-kenchu-to raises levels of calcitonin gene-related peptide and substance P in human plasma. Biol Pharm Bull 27:1875–1877

    Article  CAS  PubMed  Google Scholar 

  12. Sato Y, Inoue S, Katagiri F et al (2006) Effects of pirenzepine on Dai-kenchu-to-induced elevation of the plasma neuropeptide levels in humans. Biol Pharm Bull 29:166–171

    Article  CAS  PubMed  Google Scholar 

  13. Suehiro T, Matsumata T, Shikada Y et al (2005) The effect of the herbal medicines dai-kenchu-to and keishi-bukuryo-gan on bowel movement after colorectal surgery. Hepatogastroenterology 52:97–100

    PubMed  Google Scholar 

  14. Endo S, Nishida T, Nishikawa K et al (2006) Dai-kenchu-to, a Chinese herbal medicine, improves stasis of patients with total gastrectomy and jejunal pouch interposition. Am J Surg 192:9–13

    Article  PubMed  Google Scholar 

  15. Kaiho T, Tanaka T, Tsuchiya S et al (2005) Effect of the herbal medicine Dai-kenchu-to on serum ammonia in hepatectomized patients. Hepatogastroenterology 52:161–165

    PubMed  Google Scholar 

  16. Kono T, Kanematsu T, Kitajima M (2009) Exodus of Kampo, traditional Japanese medicine, from the complementary and alternative medicines: is it time yet? Surgery 146:837–840

    Article  PubMed  Google Scholar 

  17. Manabe N, Camilleri M, Rao A et al (2010) Effect of daikenchuto (TU-100) on gastrointestinal and colonic transit in humans. Am J Physiol Gastrointest Liver Physiol 298:G970–G975

    Article  CAS  PubMed  Google Scholar 

  18. Liver Cancer Study Group of Japan (1997) Classification of primary liver cancer, 1 English edn. Kanehara, Tokyo

    Google Scholar 

  19. Nagano T, Itoh H, Takeyama M (2000) Effects of Dai-kenchu-to on levels of 5-hydroxytryptamine (serotonin) and vasoactive intestinal peptides in human plasma. Biol Pharm Bull 23:352–353

    Article  CAS  PubMed  Google Scholar 

  20. Nagano T, Itoh H, Takeyama M (1999) Effect of Dai-kenchu-to on levels of 3 brain-gut peptides (motilin, gastrin and somatostatin) in human plasma. Biol Pharm Bull 22:1131–1133

    Article  CAS  PubMed  Google Scholar 

  21. Itoh T, Yamakawa J, Mai M et al (2002) The effect of the herbal medicine daikenchu-to on post-operative ileus. J Int Med Res 30:428–432

    Article  CAS  PubMed  Google Scholar 

  22. Yoshikawa K, Shimada M, Nishioka M et al (2012) The effects of the Kampo medicine (Japanese herbal medicine) “Daikenchuto” on the surgical inflammatory response following laparoscopic colorectal resection. Surg Today 42:646–651

    Article  PubMed  Google Scholar 

  23. Kito Y, Suzuki H (2006) Effects of Dai-kenchu-to on spontaneous activity in the mouse small intestine. J Smooth Muscle Res 42:189–201

    Article  PubMed  Google Scholar 

  24. Fukuda H, Chen C, Mantyh C et al (2006) The herbal medicine, Dai-Kenchu-to, accelerates delayed gastrointestinal transit after an operation on rats. J Surg Res 131:290–295

    Article  PubMed  Google Scholar 

  25. Tokita Y, Yuzurihara M, Sakaguchi M et al (2007) The pharmacological effects of Daikenchuto, a traditional herbal medicine, on delayed gastrointestinal transit in rat postoperative ileus. J Pharmacol Sci 104:303–310

    Article  CAS  PubMed  Google Scholar 

  26. Satoh K, Kase Y, Hayakawa T et al (2001) Dai-kenchu-to enhances accelerated small intestinal movement. Biol Pharm Bull 24:1122–1126

    Article  CAS  PubMed  Google Scholar 

  27. Kawasaki N, Nakada K, Nakayoshi T et al (2007) Effect of Dai-kenchu-to on gastrointestinal motility based on differences in the site and timing of administration. Dig Dis Sci 52:2684–2694

    Article  PubMed  Google Scholar 

  28. Shibata C, Sasaki I, Naito H et al (1999) The herbal medicine Dai-Kenchu-Tou stimulates upper gut motility through cholinergic and 5-hydroxytryptamine 3 receptors in conscious dogs. Surgery 126:918–924

    Article  CAS  PubMed  Google Scholar 

  29. Kinoshita Y, Inui T, Chiba T (1993) Calcitonin gene-related peptide: a neurotransmitter involved in capsaicin-sensitive afferent nerve-mediated gastric mucosal protection. J Clin Gastroenterol 17:S27–S32

    Article  PubMed  Google Scholar 

  30. Reinshagen M, Patel A, Sottili M et al (1994) Protective function of extrinsic sensory neurons in acute rabbit experimental colitis. Gastroenterology 106:1208–1214

    CAS  PubMed  Google Scholar 

  31. Kono T, Koseki T, Chiba S et al (2008) Colonic vascular conductance increased by Daikenchuto via calcitonin gene-related peptide and receptor-activity modifying protein 1. J Surg Res 150:78–84

    Article  CAS  PubMed  Google Scholar 

  32. Genesca J, Gonzalez A, Catalan R et al (1999) Adrenomedullin, a vasodilator peptide implicated in hemodynamic alterations of liver cirrhosis: relationship to nitric oxide. Dig Dis Sci 44:372–376

    Article  CAS  PubMed  Google Scholar 

  33. Kono T, Kaneko A, Hira Y et al (2010) Anti-colitis and -adhesion effects of daikenchuto via endogenous adrenomedullin enhancement in Crohn’s disease mouse model. J Crohns Colitis 4:161–170

    Article  PubMed  Google Scholar 

  34. Kono T, Omiya Y, Hira Y et al (2011) Daikenchuto (TU-100) ameliorates colon microvascular dysfunction via endogenous adrenomedullin in Crohn’s disease rat model. J Gastroenterol 46:1187–1196

    Article  PubMed  Google Scholar 

  35. Ogasawara T, Morine Y, Ikemoto T et al (2008) Influence of Dai-kenchu-to (DKT) on human portal blood flow. Hepatogastroenterology 55:574–577

    PubMed  Google Scholar 

  36. Narita M, Hatano E, Tamaki N et al (2009) Dai-kenchu-to attenuates rat sinusoidal obstruction syndrome by inhibiting the accumulation of neutrophils in the liver. J Gastroenterol Hepatol 24:1051–1057

    Article  PubMed  Google Scholar 

  37. Seo YS, Shah VH (2012) The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol 18:337–346

    Article  PubMed Central  PubMed  Google Scholar 

  38. Bellot P, Francés R, Such J (2013) Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 33:31–39

    Article  CAS  PubMed  Google Scholar 

  39. Basu S (2003) Carbon tetrachloride-induced lipid peroxidation: eicosanoid formation and their regulation by antioxidant nutrients. Toxicology 189:113–127

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was jointly supported by the Japanese Foundation for Multidisciplinary Treatment of Cancer.

Conflict of interest

Mitsuo Shimada received the research grant by TSUMURA & CO. (Tokyo, Japan). The other authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mitsuo Shimada.

Additional information

For the JFMC40-1001 group.

Appendix

Appendix

The members of this multicenter, phase III trial (JFMC40-1001) group were as follows:

Steering Committee: Mitsuo Kusano, Junichi Sakamoto, Mitsuo Shimada, Toru Kono, Takashi Kaiho, Toshiya Kamiyama, Hiroaki Nagano, Minoru Tanabe, Yuji Morine;

Medical Advisors: Masaki Kitajima, Takashi Kanematsu, Shigetoyo Saji;

Independent Data and Safety Monitoring Committee: Masaru Miyazaki, Kazuhiro Hanasaki;

Statistical Analyst: Satoshi Morita.

Principal Investigators (all in Japan): Hokkaido University Hospita—T. Kamiyama, K. Nakanishi; Supporo Medical University—K. Hirata, T. Mizuguchi; Kushiro Rosai Hospital—K. Ogasawara; Hitachi General Hospital—M. Okumura, K. Ueda; Fukaya Red Cross Hospital—H. Ito; Kameda General Hospital—N. Kano, S. Yamada; Kimitsu Chuo Hospital—T. Kaiho; Toho University Omori Medical Center—H. Kaneko, Y. Otsuka; Tokyo Medical University Hachioji Medical Center—M. Shimazu, Y. Abe; Toyama University Hospital—K. Tsukada, K. Matsui; Fujita Health University—A. Sugioka, T. Tokoro; Fujita Health University School of Medicine Banbuntane Hotokukai Hospital—Z. Morise; Kyoto University Hospital—E. Hatano, K. Taura; Osaka Medical Center for Cancer and Cardiovascular Diseases—T. Yamada, K. Goto; Osaka City University Hospital—S. Kubo, T. Uenishi; Osaka General Medical Center—K. Nishikawa, T. Deguchi; Osaka University—H. Nagano, S. Kobayashi; Osaka Medical College—K. Uchiyama, M. Hayashi; National Hospital Organization Osaka Minami Medical Center—K. Tabuse, Y. Shono; Tokushima University Hospital—M. Shimada, Y. Morine; Kyusyu University Hospital—Y. Maehara, K. Shirabe; Iizuka Hospital—K. Kajiyama, N. Harimoto; Nagasaki University Graduate School of Biomedical Science—S. Eguchi, M. Takatsuki; Kumamoto University Hospital—H. Baba, T. Beppu; Oita University Hospital—S. Kitano, M. Ota; Kagoshima University Hospital—S. Natsugoe, S. Ueno.

About this article

Cite this article

Shimada, M., Morine, Y., Nagano, H. et al. Effect of TU-100, a traditional Japanese medicine, administered after hepatic resection in patients with liver cancer: a multi-center, phase III trial (JFMC40-1001). Int J Clin Oncol 20, 95–104 (2015). https://doi.org/10.1007/s10147-014-0678-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-014-0678-2

Keywords

Navigation